66 results on '"Vassilakopoulos, Theodoros P."'
Search Results
2. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
3. Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
4. Modulation of the CGAS-Sting Anti-Tumor Immune Response Pathway in an NF-KB-Dependent or -Independent Manner As a Potential Therapeutic Target in Classical Hodgkin Lymphoma (cHL)
5. Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
6. The Prognostic Significance of Serum Beta-2 Microglobulin (sβ2m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs
7. Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)
8. Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
9. Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)
10. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL
11. Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
12. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3− T cells represents a potential antitumor mechanism of azacitidine
13. Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes
14. Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group
15. The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome
16. Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study
17. Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece
18. Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
19. Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study
20. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
21. Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
22. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
23. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma
24. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
25. Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients
26. CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling Biosignature
27. Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment
28. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?
29. Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon?
30. Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients’ Course
31. The Presence Of Spine Bone Plasmacytomas At The Time Of Multiple Myeloma (MM) Diagnosis Confers Poor Prognosis
32. A Comprehensive Immunohistochemical Approach of AKT/mTOR Pathway and p-STAT3 in Mycosis Fungoides.
33. The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine
34. Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients
35. Impact of Novel M-Component Based Biomarkers On to Progression Free Survival After Treatment in Intact Immunoglobulin Multiple Myeloma.
36. A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays
37. Regulation of Apoptosis and Oxidative Stress by LMP1 Oncoprotein of Epstein-Barr Virus in Patients with Low Grade B-Cell Leukemic Lymphomas
38. Chronic Lymphocytic Leukemia: Proliferative and Apoptotic Profile on Lymph Node, Studied by Immunohistochemistry Including the Proliferation Centers
39. Treatment of Splenic Marginal Zone Lymphoma with Rituximab Monotherapy in 59 Patients
40. Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study
41. Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study
42. First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).
43. Increased Immunohistochemical CD138 Expression in Waldenström's Macroglobulinemia (WM) in Comparison with Splenic Marginal Zone Lymphoma (SMZL).
44. The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).
45. Efficacy of Rituximab in Hairy Cell Leukemia.
46. Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN-α). The Importance of Maintenance.
47. Evaluation of Microsatellite Instability in Gastric MALT Lymphomas.
48. Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).
49. Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).
50. B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.